RxDoctor Payments Data

Jamilya Swygert

Primary Care · West Columbia, SCNPI 1942855986

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $193 and has fallen 53.6% since, to $89 in 2025. That places this record below the midpoint for primary care clinicians in SC, where the typical reported total is $632.

$652in general payments, 2019–2025

Across 38 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$132
  • Lilly USA, LLC$96
  • AbbVie$80
  • Novo Nordisk$67
  • AstraZeneca$50
  • Merck$43
  • plus $183 from 9 others

What the payments were for

  • Food & beverage$652100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$652 in reported general payments places this provider in the 50th percentile of 115 primary care providers in South Carolina.

See all primary care providers in South Carolina

Medicare billing

Part B allowed, 2024
$224
Medicare patients
13
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin35$47,680
OzempicSemaglutide33$35,705
EliquisApixaban17$13,111
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$4,563
Arnuity ElliptaFluticasone Furoate13$2,734
Atorvastatin Calcium139$1,479
Levemir FlexpenInsulin Detemir13$1,191
Albuterol Sulfate HfaAlbuterol Sulfate34$882
Omeprazole42$873
Gabapentin38$709
Amlodipine Besylate116$701
Fluticasone Propionate38$572
Valsartan26$473
Metoprolol Succinate45$473
Hydroxyzine Hcl16$461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$67$35,70533 claims
PfizerEliquis$132$13,11117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 115 primary care providers in South Carolina.

Other primary care in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →